DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Virtual Event

2020年11月16日 (月) 午後 3:00 - 2020年11月18日 (水) 午後 7:30

(Central European Time)

4051 Basel, Switzerland

Global Clinical Trial Disclosure & Data Transparency Conference

Session 3: Joint Session - Panel Discussion & Key Takeways of 5 years of CTR, Future Strategy, possible changes

Session Chair(s)

Nick  Sykes, MS

Nick Sykes, MS

Policy Advisor, Regulatory Strategy, EFPIA, Belgium

The Clinical Trials Regulation was finalised in 2014 but is to be implemented more than seven years later. During that time the design and conduct of clinical trials has evolved; complex innovative design trials have become more mainstream, use of digital technologies have shown the potential for great efficiencies in the running, monitoring and the collection of data without compromising the rights or safety of participants. This session will convene a panel of experts who will consider how the clinical trial ecosystem has evolved and will continue to evolve and how the provisions outlined in the Clinical Trials Regulation and the structures developed to support the implementation of the Regulation may need to be adapted to maintain Europe’s competitiveness as a location for clinical research.

Speaker(s)

Pieter  Vankeerberghen

Pieter Vankeerberghen

Head of Clinical Trials, European Medicines Agency, Netherlands

Contributing Panelist:

Judith  Creba, PhD

Judith Creba, PhD

Sr. Global Program Regulatory Director, Reg Affairs GDD Region EU, Novartis Pharma AG, Switzerland

Contributing Panelist:

Ruediger  Pankow, DRSc

Ruediger Pankow, DRSc

Clinical Trial Regulatory Consultant | CTIS SME, Independent Consultant, Germany

Contributing Panelist:

Kristof  Bonnarens, MPharm

Kristof Bonnarens, MPharm

Policy Officer Pharmaceuticals, European Commission, Belgium

Contributing Panelist:

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。